交银国际：上调药明生物目标价至259港元 重申“买入”评级
© Reuters. 交银国际：上调药明生物(02269)目标价至259港元 重申“买入”评级
智通财经APP获悉，交银国际发表报告，上调药明生物 (HK:2269)目标价27.6%，由203港元调高至259港元，重申“买入”评级。
报告提到，由于需求旺盛、公共卫生事件相关的新项目及长期疫苗CMO合同的推动，截至今年10月15日集团未完成总订单增至103亿美元，几乎是去年的两倍。管理层将今年下半年及明年净利润同比增长指引上调至40%以上及50%。
集团获得由全球竞争对手转移的10个项目，包括6个临床III期项目和3个临床II期项目，该行相信CMO业务收入增长和效率将进一步提高。该行上调对其2020至2022年净利润预测5至12%。
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.